THIOGENESIS THERAPEUTICS
Thiogenesis Therapeutics is a clinical-stage biotech company that develops thiol-active therapeutics to treat medical diseases.
THIOGENESIS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2018-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.thiogenesis.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
470.58 K USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Allgenesis Biotherapeutics
Allgenesis Biotherapeutics is a clinical-stage ophthalmology company that develops small molecules and biologics for ophthalmic diseases.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Dimension Therapeutics
Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
VISKA Bio
VISKA Bio is an early-stage immunotherapy platform that engages localized immunogenic cell death to treat and prevent cancer.
Official Site Inspections
http://www.thiogenesis.com
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Thiogenesis Therapeutics"
Thiogenesis Therapeutics - Crunchbase Company Profile & Funding
Organization. Thiogenesis Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Thiogenesis Therapeutics focuses on …See details»
Thiogenesis Therapeutics
Thiogenesis Therapeutics is a clinical-stage biotech company developing New Chemical Entities (NCEs) that are thiol compounds with strong antioxidant and anti-inflammatory properties. Thiogenesis’ novel compounds have the …See details»
Thiogenesis Therapeutics
Dr. Starr, (Sonoma, California), Chairman of the Thiogenesis Therapeutics board, has helped bring 6 orphan product drugs to market, and as co-founder and CEO of Raptor Pharmaceuticals (purchased by Horizon Pharma), oversaw the …See details»
Thiogenesis Therapeutics
Thiogenesis Announces Closing of $4.5 million Non-Brokered Private Placement (December 20, 2023) Thiogenesis Announces New Addition to its Scientific Advisory Board (November 27, …See details»
Thiogenesis Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Dec 20, 2023: Venture Round - …See details»
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
Thiogenesis Therapeutics, Corp. (TSXV: TTI) is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. The Company is …See details»
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
3 days ago San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical …See details»
Thiogenesis Announces Investor Relations Engagement
Sep 27, 2024 Newsfile Press Release.See details»
Thiogenesis Announces Important Core Patent Allowed in Europe
Nov 4, 2024 San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage …See details»
Thiogenesis Therapeutics, Corp. (TTI.V) Stock Price, News, Quote ...
Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs. The company's lead product candidate …See details»
Thiogenesis Therapeutics
Thiogenesis Therapeutics is a clinical-stage biotechnology company developing novel compounds, that are prodrugs and that act as precursors to certain thiols, with the intention of …See details»
Thiogenesis Gains DTC Eligibility and Expands U.S. Presence
3 days ago Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now At 40% …See details»
Thiogenesis Announces Closing of Non-Brokered Private …
Dec 18, 2023 San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" …See details»
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
3 days ago Thiogenesis' lead compound, TTI-0102, was developed to address the challenges facing thiol-based drugs, including their short half lives, adverse side effects and dosing …See details»
Thiogenesis Gains DTC Eligibility and Expands U.S. Presence
3 days ago Thiogenesis Therapeutics has achieved DTC eligibility in the U.S., facilitating electronic settlement of its shares and aligning with plans for a U.S. listing. The company is …See details»
Thiogenesis Therapeutics
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will govern Thiogenesis’ clinical trials in their respective jurisdictions. As a prodrug, TTI-0102 is eligible to …See details»
Thiogenesis Announces Closing of Final Tranche in $4.5 Million …
Dec 20, 2023 San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to …See details»
Thiogenesis Announces Positive Results from Phase 1 Dose …
May 18, 2022 Data demonstrates potential for less frequent drug administrationTTI-0102 was well tolerated with no Serious Adverse Events reportedSupports EU and US regulatory …See details»
Thiogenesis Gains DTC Eligibility and Expands U.S. Presence - MSN
Thiogenesis Therapeutics Corp (TSE:TTI) has released an update. Thiogenesis Therapeutics has achieved DTC eligibility in the U.S., facilitating electronic settlement of its shares and aligning ...See details»
Thiogenesis Therapeutics
Thiogenesis has synthesized novel compounds, that are New Chemical Entities (“NCEs”) and act as precursors to thiols. Thiols are compounds that have a functional R-SH group, where S is …See details»